Clinical Trials Browser

Active not recruiting × Interventional × Pluvicto × Clear all

NCT05114746 2026-03-16

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04720157 2026-03-11

PSMAddition

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05849298 2026-03-03

PSMACare

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04689828 2026-02-20

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT06894511 2026-02-17

PSMAndARPI

Phase 2 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05682443 2025-12-02

PRESERVE-006

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04663997 2025-11-06

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Prostatic Neoplasms

NCT04343885 2025-07-11

UpFrontPSMA

Phase 2 Active not recruiting

Metastatic Hormone Naive Prostate Cancer

NCT05340374 2025-04-06

LuCAB

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04430192 2024-11-08

LuTectomy

Phase 1/2 Active not recruiting

Prostatic Neoplasms